Dario

Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes

Retrieved on: 
Thursday, April 25, 2024
School, JMIR, University, University Challenge 2013–14, Prediabetes, Public health, Blood pressure, Dario, Overweight, BMI, Diabetes, Partnership, Empowerment, Research, A1C, Obesity, Blood, Type 2 diabetes, Medicine, Journal, Medical device

NEW YORK, April 25, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR) demonstrating a clinically significant reduction in blood glucose levels for members using Dario to manage weight alongside diabetes.

Key Points: 
  • Dario's cardiometabolic solution helps people manage related cardiometabolic health needs, including diabetes, pre-diabetes, blood pressure, weight and support for people taking a GLP-1, with a single integrated and highly personalized experience.
  • Dario's solution is designed to help people adopt the healthier behaviors required to support improved clinical outcomes, which includes self-health management behaviors such as monitoring weight and blood glucose.
  • This new retrospective, quasi-randomized study examined the data from 1,932 Dario members over the course of a year.
  • The research was conducted in partnership with Integrative Pain Laboratory, the School of Public Health at the University of Haifa.

Dario Publishes New Research Demonstrating that Dario Users That Increased Physical Activity Can Maintain Reduced Blood Glucose

Retrieved on: 
Monday, November 13, 2023
Diet, School, University of Haifa, Research, Health, University, Blood, Partnership, School of Public Health, Public health, Diabetes Technology Society, Diabetes, Prediabetes, Blood pressure, Medical device, Dario

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced new research presented at the Diabetes Technology Society 2023 Meeting on November 7, 2023. The new research demonstrated the value of associating physical activity tracking alongside blood sugar tracking for people living with diabetes and pre-diabetes.

Key Points: 
  • The new research demonstrated the value of associating physical activity tracking alongside blood sugar tracking for people living with diabetes and pre-diabetes.
  • The results demonstrated significantly reduced blood glucose levels in the first four months of using Dario and increased step levels in the same timeframe maintained for 12 months.
  • In addition, the results demonstrated clinically significant reductions in blood glucose levels in users who tracked at least 400 steps per day.
  • The research was conducted in partnership with the Integrative Pain Laboratory, School of Public Health at the University of Haifa.

DarioHealth Reports Third Quarter 2023 Financial and Operating Results

Retrieved on: 
Thursday, November 2, 2023
Well, Nexus, Digital, Ratio, Nine Months, Operating cost, Journal of Medical Internet Research, Three Months, B2C, Medicine, Conference, Diabetes, GAAP, Acquisition, Research, Journal, Academy of Managed Care Pharmacy, Nike, Glycated hemoglobin, Type 2 diabetes, Prediabetes, Growth, Hypertension, Webcast, Marketing, The Walt Disney Company, JMIR, Aetna, Breathing, Partnership, Depreciation, Sanofi, Solera, Depression, 4836 Medon, Total, Anxiety, YTD, Video game, Food delivery, Pharmaceutical industry, Cryptocurrency, Risk management, Clothing, Property insurance, Bank, Dario

NEW YORK, Nov. 2, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the third quarter 2023 and provided a corporate and commercial update.

Key Points: 
  • NEW YORK, Nov. 2, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the third quarter 2023 and provided a corporate and commercial update.
  • Total operating expenses for the third quarter of 2023 were $16.2 million, compared with $16.4 million for the third quarter of 2022, and $16.1 million for the second quarter of 2023, a decrease of $0.2 million, or 1.3%, compared to the third quarter of 2022, and an increase of $62,000, or 0.4%, compared to the second quarter of 2023.
  • Total operating expenses excluding stock-based compensation, earn-out measurement, and depreciation for the third quarter of 2023 were $10.9 million, compared to $11.4 million for the third quarter of 2022, and $10.7 million for the second quarter of 2023.
  • Operating loss excluding stock-based compensation and depreciation for the third quarter of 2023 was $9.15 million compared to $8.4 million for the third quarter of 2022, and $7.5 million for the second quarter of 2023.

Dario Launches Apple iPhone 15 Accessible Smart Blood Glucose Meter

Retrieved on: 
Wednesday, November 1, 2023
IPhone, Apple, Mobile phone, Dario

NEW YORK, Nov. 1, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced the launch of a new smart blood sugar meter for Apple iPhone 15 users to support ongoing engagement with new and existing members.

Key Points: 
  • NEW YORK, Nov. 1, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced the launch of a new smart blood sugar meter for Apple iPhone 15 users to support ongoing engagement with new and existing members.
  • As recently reported, the new iPhone 15 is built with a USB-C charging port, a key element for real-time data capture in Dario's smart blood glucose meter.
  • Dario's new smart blood sugar meter offers iPhone 15 users the same instant connectivity for real-time blood sugar readings as part of their personalized Dario health management experience by giving members a USB-C compatible device.
  • Our new iPhone 15 smart blood sugar meter is just another example of our ability to respond quickly to consumer needs and keep our members engaged over time," said Rick Anderson, President of Dario.

Dario Publishes New Research Demonstrating Clinically Significant Reductions in Depression Through its Digital Behavioral Health Programs

Retrieved on: 
Wednesday, September 27, 2023
Medicine, Depression, Bureau of Oceans and International Environmental and Scientific Affairs, Journal of Medical Internet Research, Cognitive behavioral therapy, Anxiety, Breathing, Research, CBT, Journal, Behavior, Motivation, Knowledge, Digital, Mental health, JMIR, Nursing, Pig, Tutoring, Dario

NEW YORK, Sept. 27, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced new research published in the Journal of Medical Internet Research (JMIR) demonstrating the impact of coaching and breathing exercises as part of the Dario digital behavioral health program alongside coaching and breathing exercises for members living with depression or anxiety.

Key Points: 
  • Dario's behavioral health solution uses an evidence-based triage screener to assess individual mental health needs and recommend the right type of care for each person.
  • Dario's digital Cognitive Behavioral Therapy (CBT) based programs offer members self-guided programs designed to teach proven techniques for managing emotional health.
  • The study analyzed the data of participants in two cohorts engaged in Dario's digital self-guided programs who started at a moderate or high level of depression or anxiety.
  • "Digital health solutions, particularly in behavioral health, have tremendous potential to help people access support when and how they need it.

Dario Publishes New Research Demonstrating Greater Engagemenet and Improved Clinical Outcomes Sustainable for Two Years

Retrieved on: 
Thursday, August 24, 2023
Conference, Bureau of Oceans and International Environmental and Scientific Affairs, Research, Diabetes, Doctor of Philosophy, Behavior, Dario

NEW YORK, Aug. 24, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced new research presented at the ADCES23 Annual Conference held earlier this month in Houston, Texas. The new research demonstrates Dario's ability to sustainably improve health outcomes for users with diabetes over a two-year period.

Key Points: 
  • The new research demonstrates Dario's ability to sustainably improve health outcomes for users with diabetes over a two-year period.
  • Dario's digital health solutions combine a clinically intelligent platform with billions of consumer insights to help drive sustainable behavior change to improve the management of chronic conditions and improve health outcomes.
  • The latest research analyzed the data of 119,482 Dario members to understand the relationship between improving engagement and health outcomes.
  • The results showed that during the two years of data analyzed in the research study, users improved engagement 29% over two years.

DarioHealth Reports First Quarter Financial and Operating Results

Retrieved on: 
Thursday, May 11, 2023
Well, CGM, ATTD, Partnership, Type 2 diabetes, Pharmacy, Therapy, Digital, Dexcom, GAAP, Research, Ratio, B2C, Back pain, Hospital, Acquisition, International Conference on Afghanistan, London (2006), Amwell, Pharmacy benefit management, Pain management, PBM, Webcast, Sanofi, Depreciation, Growth, Himawari (satellites), Advanced Technology Vehicles Manufacturing Loan Program, Conference, Diabetes, Total, Video game, Retail, Marketing, Pharmaceutical industry, Dario

ET today

Key Points: 
  • ET today
    NEW YORK, May 11, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the first quarter 2023 and provided a corporate and commercial update.
  • "Business-to-Business (B2B) revenues continued to increase, representing approximately 70% of our total revenue during the first quarter, up from 56% in the first quarter of 2022.
  • Total operating expenses excluding stock-based compensation, acquisition expenses, earn-out measurement, and depreciation for the first quarter of 2023 were $10.6 million, compared to $14.8 million for the first quarter of 2022, and $10 million for the fourth quarter of 2022.
  • Operating loss excluding stock-based compensation, acquisition expenses and depreciation for the first quarter of 2023 were $6.3 million compared to $9.9 million for the first quarter of 2022, and $6.0 million for the fourth quarter of 2022.

Sanofi research demonstrates 9.3% reduction in all-cause healthcare resource utilization rates, including 23.5% decrease in hospitalization for Dario users

Retrieved on: 
Tuesday, May 9, 2023
Partnership, Diabetes, ISPOR, Food and Drug Administration, Research, Data analysis, Sanofi, Conditional sentence, Health, FDA, Digital health, Food, Medical imaging, Dario

NEW YORK, May 9, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the presentation of research at ISPOR 2023 demonstrating significant reductions in healthcare resource utilization for Dario users compared to non-users, the first study completed by Sanofi U.S. ("Sanofi") under its strategic agreement with Dario. ISPOR, the leading global conference for health economics and outcomes research, is being held May 7th – 10th in Boston.

Key Points: 
  • ISPOR, the leading global conference for health economics and outcomes research, is being held May 7th – 10th in Boston.
  • The study conducted by Sanofi and presented at ISPOR demonstrates a statistically significant 9.3% reduction in all-cause Heath Care Resource Utilization (HCRU), including a 23.5% reduction in hospitalizations, in Dario users after 12 months.
  • "We are incredibly proud of this new research demonstrating Dario's ability to potentially reduce health care utilization through a holistic, user-centric digital health solution.
  • This research is the first of several studies to be released based on this data analysis to demonstrate the impact of Dario on clinical, resource utilization and financial outcomes.

Dario Announces Strategic Partnership with Amwell to Expand Access to its Cardiometabolic Digital Therapeutic Solution

Retrieved on: 
Wednesday, March 22, 2023
Single-frequency network, Partnership, Amwell, Diabetes, NYSE, Online shopping, Dario

NEW YORK, March 22, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced today a strategic partnership with Amwell® (NYSE: AMWL), a leader in digital healthcare enablement, to deliver its cardiometabolic solution to Amwell customers. Dario's solution will be available through Amwell beginning in the second half of 2023.

Key Points: 
  • NEW YORK, March 22, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced today a strategic partnership with Amwell® (NYSE: AMWL), a leader in digital healthcare enablement, to deliver its cardiometabolic solution to Amwell customers.
  • The agreement is part of Dario's strategy to partner with market leading strategic partners to accelerate adoption of Dario's solutions by making the Dario solution available to existing Amwell customers.
  • "Amwell is a recognized leader in digital care delivery enablement covering 90 million lives through its substantial footprint of clients.
  • We are proud to partner with them to take the Dario cardiometabolic suite to our target markets," said Rick Anderson, President of Dario.

Dario Publishes New Research Demonstrating Digital Personalization of Pain Management with Adapted Machine Learning

Retrieved on: 
Tuesday, March 14, 2023
Machine learning, University, Research, Back pain, Doctor of Philosophy, School, Pain management, University of Haifa, School of Public Health, MD, Bureau of Oceans and International Environmental and Scientific Affairs, Single-frequency network, Pain, Therapy, Life, Dario, Partnership, Public health, Medical device

NEW YORK, March 14, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO)(the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today new research published in Pain Reports investigating personalized efficacy of digital therapeutics for pain management, linking the reduction of back pain for users in a digital posture training program with the personalization of user journeys adapting machine learning models.

Key Points: 
  • NEW YORK, March 14, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO)(the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today new research published in Pain Reports investigating personalized efficacy of digital therapeutics for pain management, linking the reduction of back pain for users in a digital posture training program with the personalization of user journeys adapting machine learning models.
  • Dario set out to determine the effectiveness of deploying adapted machine learning to analyze and personalize user journeys in its posture training solution.
  • The results of the study offer a framework to help understand the efficacy of digital therapeutics in helping individuals manage pain.
  • The research was conducted in partnership with the Integrative Pain Laboratory, School of Public Health at the University of Haifa.